iDEL Therapeutics develops a synthetic shuttle technology that evades endosomal trapping to deliver high intracellular exposure and sustained tumor retention of therapeutic payloads. The platform is compatible with both large and small molecules, including nanobodies against oncogenes and tumor-targeted cytotoxic payloads. The company leverages a pan-cancer uptake mechanism to move drug payloads directly into the cytosol of tumor cells in patients. iDEL is led by CEO Marcus Kostka and is based in Dortmund, Germany. Following its €9M Seed raise, the company plans to expand operations and continue its development efforts. No revenue, user, or other operating metrics were disclosed in the announcement.

Total raised

$10M

Funding rounds

1

Latest round

Seed

Latest activity

Mar 2026